1. Home
  2. RCG vs BIAF Comparison

RCG vs BIAF Comparison

Compare RCG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCG
  • BIAF
  • Stock Information
  • Founded
  • RCG 1994
  • BIAF 2014
  • Country
  • RCG United States
  • BIAF United States
  • Employees
  • RCG N/A
  • BIAF N/A
  • Industry
  • RCG Investment Managers
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • RCG Finance
  • BIAF Health Care
  • Exchange
  • RCG Nasdaq
  • BIAF Nasdaq
  • Market Cap
  • RCG 15.6M
  • BIAF 14.5M
  • IPO Year
  • RCG N/A
  • BIAF 2022
  • Fundamental
  • Price
  • RCG $2.47
  • BIAF $0.99
  • Analyst Decision
  • RCG
  • BIAF Strong Buy
  • Analyst Count
  • RCG 0
  • BIAF 1
  • Target Price
  • RCG N/A
  • BIAF $6.00
  • AVG Volume (30 Days)
  • RCG 5.9K
  • BIAF 148.8K
  • Earning Date
  • RCG 01-01-0001
  • BIAF 11-14-2024
  • Dividend Yield
  • RCG 0.98%
  • BIAF N/A
  • EPS Growth
  • RCG N/A
  • BIAF N/A
  • EPS
  • RCG N/A
  • BIAF N/A
  • Revenue
  • RCG N/A
  • BIAF $9,367,785.00
  • Revenue This Year
  • RCG N/A
  • BIAF $285.51
  • Revenue Next Year
  • RCG N/A
  • BIAF $20.05
  • P/E Ratio
  • RCG N/A
  • BIAF N/A
  • Revenue Growth
  • RCG N/A
  • BIAF 2813.87
  • 52 Week Low
  • RCG $1.52
  • BIAF $0.83
  • 52 Week High
  • RCG $1.90
  • BIAF $3.62
  • Technical
  • Relative Strength Index (RSI)
  • RCG 49.06
  • BIAF 41.69
  • Support Level
  • RCG $2.48
  • BIAF $0.83
  • Resistance Level
  • RCG $2.55
  • BIAF $1.04
  • Average True Range (ATR)
  • RCG 0.07
  • BIAF 0.13
  • MACD
  • RCG -0.03
  • BIAF 0.02
  • Stochastic Oscillator
  • RCG 3.23
  • BIAF 35.25

About RCG RENN Fund Inc

RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, Oil and Gas, medical chemicals, botanical products, and others.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: